GH Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 94081 min ago

@ $22.28

Išleistas: 14 vas. 2024 @ 20:20

Grąža: -27.87%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: 1.83 %

Live Chart Being Loaded With Signals

Commentary (19 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	1.85M
Vidutinė apimtis	2.00M
Rinkos kapitalizacija	1.96B
EPS	$0 ( 2024-02-22 )
Kita pelno data	( $-0.940 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.75
ATR14	$0.0280 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Tariq Musa	Sell	249	Restricted Stock Units
2024-04-15	Tariq Musa	Buy	249	Common Stock
2024-04-15	Saia John G.	Buy	7 569	Common Stock
2024-04-15	Saia John G.	Sell	2 701	Common Stock
2024-04-15	Saia John G.	Sell	1 108	Common Stock

INSIDER POWER
-46.43
Last 99 transactions
Buy: 864 284 \| Sell: 2 349 747

Tūris Koreliacija

Ilgas: 0.47 (neutral)

Trumpas: 0.86 (strong)

Signal:(63.11) Same movement expected

Guardant Health Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Guardant Health Inc Koreliacija - Valiuta/Žaliavos

-0.77
( moderate negative )

-0.75
( moderate negative )

0.00
( neutral )

-0.75
( moderate negative )

-0.23
( neutral )

0.28
( neutral )

Guardant Health Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$563.95M
Bruto pelnas:	$336.90M (59.74 %)
EPS:	$-4.28

Q4	2023
Pajamos:	$155.05M
Bruto pelnas:	$236.19M (152.33 %)
EPS:	$-1.580

Q3	2023
Pajamos:	$143.03M
Bruto pelnas:	$85.42M (59.72 %)
EPS:	$-0.730

Q2	2023
Pajamos:	$137.15M
Bruto pelnas:	$83.30M (60.74 %)
EPS:	$-0.670

Financial Reports:

No articles found.

Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.